Your browser doesn't support javascript.
loading
Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis.
Sizova, Daria V; Raiker, Steve; Lakheram, Deaneira; Rao, Vishwanatha; Proffitt, Andrew; Jmeian, Yazen; Voegtli, Walter; Batonick, Melissa.
Afiliação
  • Sizova DV; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Raiker S; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Lakheram D; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Rao V; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Proffitt A; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Jmeian Y; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Voegtli W; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
  • Batonick M; Alexion AstraZeneca Rare Disease, 100 College Street, New Haven, CT, 06510, USA.
Biochem Biophys Rep ; 34: 101442, 2023 Jul.
Article em En | MEDLINE | ID: mdl-36875796
Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition. This disorder is caused by malfunctioning of B-cells resulting in production of abnormal protein fibrils composed of immunoglobulin light chain fragments that tend to deposit on various organs and tissues. AL amyloidosis is set apart from other forms of amyloidosis in that no specific sequences have been identified in the immunoglobulin light chains that are amyloid fibril formation causative and patient specific. This unusual feature hinders the therapeutic progress and requires either direct access to patient samples (which is not always possible) or a source of in vitro produced fibrils. While isolated reports of successful AL amyloid fibril formation from various patient-specific protein sequences can be found in literature, no systematic research on this topic was performed since 1999. In the present study we have developed a generalized approach to in vitro fibril production from various types of previously reported [[1], [2], [3]] amyloidogenic immunoglobulin light chains and their fragments. We describe the procedure from selection and generation of starting material, through finding of optimal assay conditions, to applying a panel of methods to confirm successful fibril formation. Procedure details are discussed in the light of the most recent findings and theories on amyloid fibril formation. The reported protocol produces high quality AL amyloid fibrils that can subsequently be used in the development of the much-needed amyloid-targeting diagnostic and therapeutic approaches.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Biochem Biophys Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Biochem Biophys Rep Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos